secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001193125-24-080874
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics prices $125M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Priced 5,555,557 shares at $13.50/share and pre-funded warrants for 3,703,730 shares at $13.4999.
- Expected gross proceeds of $125M; net proceeds ~$119.8M after underwriting discounts and expenses.
- Net proceeds to fund research, clinical development of STK-001 and STK-002, and other corporate purposes.
- Offering expected to close on April 2, 2024; J.P. Morgan acting as sole book-running manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524080874/0001193125-24-080874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524080874/d807060d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-080874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer